These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 1432933)
41. The FDA and Helsinki. Rennie S Hastings Cent Rep; 2009; 39(3):49. PubMed ID: 19537622 [No Abstract] [Full Text] [Related]
42. Name ADA Council sponsor of new standards committee. J Am Dent Assoc; 1969 Jul; 79(1):56. PubMed ID: 5254553 [No Abstract] [Full Text] [Related]
43. Lists of products evaluated by the Council on Dental Materials and Devices and the Council on Dental Therapeutics. J Am Dent Assoc; 1978 Feb; 96(2):354-64. PubMed ID: 272419 [No Abstract] [Full Text] [Related]
44. [Comparisons of tests of investmenting materials according to ADA Specification No. 2]. Dechent K; Klötzer WT Dent Labor (Munch); 1976 Nov; 24(11):1511-6. PubMed ID: 1078031 [No Abstract] [Full Text] [Related]
45. The paradoxical case of payment as benefit to research subjects. Macklin R IRB; 1989; 11(6):1-3. PubMed ID: 11650284 [No Abstract] [Full Text] [Related]
46. The new FDA combination products programme. Donawa M Med Device Technol; 2002 Oct; 13(8):25-8. PubMed ID: 12416330 [TBL] [Abstract][Full Text] [Related]
47. The Food and Drug Administration's regulation of dental products. Pinco RG; Rubin PD J Clin Dent; 1995; 6(3):165-9. PubMed ID: 8615957 [No Abstract] [Full Text] [Related]
48. ADA seeks clarification on FDA dental amalgam statement: recent FDA settlement of moms against mercury lawsuit spurs response. Dent Today; 2008 Jul; 27(7):73. PubMed ID: 18686661 [No Abstract] [Full Text] [Related]
49. The FDA's enforcement of IRBs and patient informed consent. Kelsey FO Food Drug Cosmet Law J; 1989 Jan; 44(1):13-20. PubMed ID: 11651627 [No Abstract] [Full Text] [Related]
50. A look at the bioresearch monitoring program: the agency perspective. Brisson EL Food Drug Cosmet Law J; 1983 Apr; 38(2):184-9. PubMed ID: 11649578 [No Abstract] [Full Text] [Related]
51. Evaluation programs at the American Dental Association. Wozniak WT J Clin Dent; 1995; 6(3):170-3. PubMed ID: 8615958 [No Abstract] [Full Text] [Related]
53. Informed consent: the FDA's perspective. Bagley G Food Drug Law J; 1993; 48(2):181-6. PubMed ID: 11653141 [No Abstract] [Full Text] [Related]
54. Informed consent in the clinical research setting: experimentation on human subjects. Owens JF Med Trial Tech Q; 1987; 33(3):335-50. PubMed ID: 11653829 [No Abstract] [Full Text] [Related]
55. How the FDA and the ADA affect development of prescription drugs for oral care. Cooley WE J Public Health Dent; 1992; 52(6):350-2. PubMed ID: 1432922 [TBL] [Abstract][Full Text] [Related]
56. The expert surrogate system: a role for the Golden Rule in clinical practice. Mackillop WJ Humane Med; 1988 Nov; 4(2):89-95. PubMed ID: 11650833 [No Abstract] [Full Text] [Related]
57. Text of address to ADA Third Conference of National Dental Organizations. Tabak JD ASDC J Dent Child; 1976; 43(6):396-400. PubMed ID: 135773 [No Abstract] [Full Text] [Related]